April 21, 2015
ARLINGTON, Va. — HDMA President and CEO John M. Gray hailed the April 21 passage of the Ensuring Patient Access and Effective Drug Enforcement Act of 2015 (H.R. 471) by the U.S. House of Representatives. H.R. 471 is sponsored by Reps. Tom Marino (R-Pa.), Marsha Blackburn (R-Tenn.), Peter Welch (D-Vt.) and Judy Chu (D-Calif.)
“HDMA is pleased that the House of Representatives has once again passed this bipartisan legislation to help unite the pharmaceutical supply chain and regulators, such as the Drug Enforcement Administration, in their common goal of seeking to reduce prescription drug abuse and diversion. The nation’s primary pharmaceutical distributors, through HDMA, now call on the Senate to take up companion legislation ― S. 483, sponsored by Sens. Hatch (R-Utah) and Whitehouse (D-R.I.) ― in the hopes of promoting greater transparency in the fight against drug abuse and diversion.”
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.